CorInnova Incorporated is involved in innovative Device-Based Therapies for the Treatment of Congestive Heart Failure. CorInnova is has developed a breakthrough technological platform for the treatment of heart failure. Congestive heart failure is a gradually progressive condition in which the heart muscle weakens, leading to a decrease in contraction force and inadequate delivery of oxygen-rich blood to the body. Utilizing the knowledge that aberrant cardiac motion leads to congestive heart failure by causing abnormal growth and remodeling of the heart, CorInnova has developed the CardiacSTAR (TM), a minimally invasive, direct cardiac compression device that restores normal cardiac motion to the heart through the application of gentle pressure. The CardiacSTAR will be the first heart assist device on the market that promotes healthy cardiac motion rather than heart ejection or flow. This restoration of normal cardiac motion enables the reversal of muscle damage, allowing the heart to remodel itself back to a normal, healthy state. This earlier-stage medical device company’s technology is poised to replace or work in conjunction with already-existent treatments including invasive surgery, pharmaceuticals, and electrical and stem cell therapies. Unlike prior direct cardiac compression devices, CorInnova’s technology does not invert the curvature of the heart. Instead, CorInnova’s technology corrects bad cardiac motion and promotes correct cardiac motion. This is termed cardiac rekinesis therapy. Moreover, unlike other cardiac assist devices, CorInnova’s device does not touch the blood, eliminating the risk of thrombosis, stroke, and bleeding, and making it non-obligatory. The device is also bi-ventricular. The unique design of the device promotes diastolic recoil, which promotes heart filling.